Janux Therapeutics

JANX · Nasdaq · United States

Share price · JANX

$10.31-6.65 (-39.21%) 3M

close as of 2026-11-18 · 24h delayed · vol 981K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when JANX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026-27.6%
  2. 6 Nov 2026+9.8%
  3. 7 Oct 2026+6.7%

    Nothing announced by JANX that day or the session before.

  4. 10 Sep 2026-8.5%

    Nothing announced by JANX that day or the session before.

  5. 24 Aug 2026+7.0%
  6. 18 Aug 2026+4.3%

    Nothing announced by JANX that day or the session before.

  7. 8 Jul 2026+3.2%

    Nothing announced by JANX that day or the session before.

  8. 1 Jul 2026-4.6%

    Nothing announced by JANX that day or the session before.

  9. 2 Dec 2025-53.3%

    Nothing announced by JANX that day or the session before.

  10. 25 Nov 2025+10.2%

    Nothing announced by JANX that day or the session before.

Share of unusual movement by asset

For each asset, the share of JANX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
JANX007
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—24%
Other company news (earnings, financing, releases naming no asset)—13%
Sessions with no dated event—63%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
PSMA x CD3Multispecific antibody
Prostate Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$9.3M$31M$42M+ $904M short-term inv.$22M-$25M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$10M$31M$28M+ $943M short-term inv.$22M$12M operating cash flowreport ↗
2026-Q1$3.7M$27M$52M+ $905M short-term inv.$24M-$12M operating cash flowreport ↗
2025-Q3$10M$35M$48M+ $941M short-term inv.$24M-$13M operating cash flowreport ↗
2025-Q2$0$35M$52M+ $944M short-term inv.$34M-$24M operating cash flowreport ↗
2025-Q1$0$25M$74M+ $940M short-term inv.$24M-$17M operating cash flowreport ↗
2024-Q3$0.4M$19M$27M+ $631M short-term inv.$28M-$2.2M operating cash flowreport ↗
2024-Q2$8.9M$15M$15M+ $632M short-term inv.$6.0M-$10M operating cash flowreport ↗
2024-Q1$1.3M$14M$213M+ $439M short-term inv.$15M-$15M operating cash flowreport ↗
2023-Q3$2.5M$12M$17M+ $333M short-term inv.$12M-$12M operating cash flowreport ↗
2023-Q2$1.1M$15M$34M+ $270M short-term inv.$18M-$15M operating cash flowreport ↗
2023-Q1$2.0M$16M$30M+ $287M short-term inv.$17M-$14M operating cash flowreport ↗
2022-Q3$1.8M$14M$65M+ $274M short-term inv.$17M-$13M operating cash flowreport ↗
2022-Q2$2.4M$14M$58M+ $296M short-term inv.$17M-$6.1M operating cash flowreport ↗
2022-Q1$1.6M$10M$55M+ $306M short-term inv.$13M-$12M operating cash flowreport ↗
2021-Q3$1.2M$8.4M$39M+ $348M short-term inv.$11M-$5.8M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$10M$126M$52M+ $914M short-term inv.$28M-$82M operating cash flowreport ↗

Janux Therapeutics reported 2025 collaboration revenue of $10.0M, down 5.6% YoY from $10.59M, and R&D expenses of $125.9M, up 84.1% YoY from $68.39M. Cash and equivalents were $52.33M at year-end, with short-term investments of $914.23M and total cash, equivalents and short-term investments of $966.6M. The company reported a full-year net loss of $113.62M and a quarterly net burn of $113.63M.

Janux presented updated interim Phase 1 data for JANX007 in December 2025, covering 109 patients as of the October 15, 2025 cutoff, with median radiographic progression-free survival of 7.9 to 8.9 months and confirmed or unconfirmed partial responses in 30% (8/27) of RECIST-evaluable patients; JANX007 is enrolling a Phase 1b taxane-naïve mCRPC population, JANX008 is enrolling expansion cohorts in defined solid tumors, and JANX011 has initiated a Phase 1 healthy-volunteer study. In January 2026, Janux entered a collaboration and exclusive worldwide license with Bristol Myers Squibb for a novel tumor-activated therapeutic, with $50M in upfront and near-term milestone payments, potential milestones of approximately $800M, and tiered royalties. William Go, M.D., Ph.D. was appointed Chief Medical Officer, and the company expects additional JANX007 data in 2026, a JANX008 clinical update in 2026, and an initial JANX011 update by year-end 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$11M$68M$431M+ $595M short-term inv.$17M-$44M operating cash flowreport ↗
2023-FY$8.1M$55M$19M+ $325M short-term inv.$15M-$51M operating cash flowreport ↗
2022-FY$8.6M$53M$51M+ $276M short-term inv.$16M-$43M operating cash flowreport ↗
2021-FY$3.6M$26M$36M+ $339M short-term inv.$8.2M-$17M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 10 sales ($457K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-07-31Campbell David Alan · director, President and CEOGift123,840——Form 4
2026-07-08Campbell David Alan · director, President and CEOOption exercise7,000$4.21$29KForm 4
2026-07-08Campbell David Alan · director, President and CEOOption exercise (derivative)7,000——Form 4
2026-06-11Barrett Ronald W · directorAward / grant5,500——Form 4
2026-06-11CAPPS VICKIE L · directorAward / grant5,500——Form 4
2026-06-11DOBMEIER ERIC · directorAward / grant5,500——Form 4
2026-06-11Hernday Natasha · directorAward / grant5,500——Form 4
2026-06-11Kung Winston · directorAward / grant5,500——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 189 reporting institutions held 59.6M shares ($812.2M, 97.4% of shares outstanding).

#InstitutionSharesValue
1RA CAPITAL MANAGEMENT, L.P.11,189,693$155.5M
2BlackRock, Inc.5,433,233$75.5M
3JANUS HENDERSON GROUP PLC4,196,409$58.3M
4Prosight Management, LP3,550,000$49.3M
5FMR LLC2,535,724$35.2M
6STATE STREET CORP2,464,017$34.2M
7VANGUARD CAPITAL MANAGEMENT LLC1,811,365$25.2M
8TCG Crossover Management, LLC1,789,617$24.9M
9Alyeska Investment Group, L.P.1,601,089$22.3M
10WELLINGTON MANAGEMENT GROUP LLP1,597,650$22.2M
11VANGUARD PORTFOLIO MANAGEMENT LLC1,290,256$17.9M
12Deep Track Capital, LP1,187,290$16.5M
13Point72 Asset Management, L.P.1,156,140$16.1M
14GEODE CAPITAL MANAGEMENT, LLC1,146,724$15.9M
15Balyasny Asset Management L.P.1,090,147$15.2M